Dyadic International logo
Dyadic International DYAI
$ 0.68 -3.21%

Annual report 2025
added 03-25-2026

report update icon

Dyadic International Cost of Revenue 2011-2026 | DYAI

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Dyadic International

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
2.32 M 1.19 M 1.98 M 2.12 M 1.94 M 1.42 M 1.46 M 1.03 M 680 K - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.32 M 680 K 1.57 M

Quarterly Cost of Revenue Dyadic International

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
1.02 M - - 396 K 302 K 144 K - 106 K 793 K 727 K - 603 K 411 K 405 K - 393 K 830 K 391 M - 267 K 624 K 278 K - 385 K 322 K 328 K - 243 K 129 K 147 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
391 M 106 K 18.2 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Verastem Verastem
VSTM
165 K $ 5.04 -4.73 % $ 349 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
90 K - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
9 K - 1.93 % $ 17.4 M usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
Albireo Pharma Albireo Pharma
ALBO
1.36 M - -0.23 % $ 916 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
602 K - - $ 7.46 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
15.3 M - -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
33.5 M - - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
76 K - 4.01 % $ 150 M canadaCanada
Avid Bioservices Avid Bioservices
CDMO
133 M - - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
100 K - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
71.4 M $ 12.41 -11.1 % $ 1.88 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
70.7 M - 0.49 % $ 251 B cayman-islandsCayman-islands
BioDelivery Sciences International BioDelivery Sciences International
BDSI
23.4 M - -4.8 % $ 255 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
737 K $ 1.05 -3.67 % $ 21.5 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
238 M - - $ 867 M germanyGermany
AbbVie AbbVie
ABBV
18.2 B $ 209.4 -0.83 % $ 370 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
677 M $ 317.36 -3.29 % $ 41.6 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
20.6 M $ 2.6 -2.8 % $ 16.3 M usaUSA